Jump to content

CSL - CSL LIMITED


ShareCafe

Recommended Posts

  • Replies 959
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

In reply to: The Pro on Friday 18/07/08 11:03am

FYI

 

$40 SP is still looking probable in the short term. Long term even better.

 

Never give up on this stock.

 

from

 

http://www.iii.co.uk/news/?type=afxnews&ar...&action=article

 

"STOCKS ON THE MOVE

 

CSL LTD <CSL.AX&GT;, THE WORLD'S TOP MAKER OF PLASMA PRODUCTS, ROSE 3.7 PERCENT TO A$36.29.

Analysts said stronger-than-expected earnings and a profit upgrade at Baxter International Inc <BAX.N> augurs well for CSL, which has similar earnings drivers.

 

Baxter on Thursday said quarterly profit rose 26 percent, led by strong demand for plasma and other blood therapy products. It also raised its profit forecast for the full year amid expectations that gross and operating margins will continue to improve [iD:nN17255796].

 

Citigroup has a buy rating on CSL, with a price target of A$43.79, while Goldman Sachs JBWere has a hold call on the firm, with a price target of A$38.66."

 

 

Red

 

 

Link to comment
Share on other sites

From:

 

http://www.medicalnewstoday.com/articles/115548.php

 

"Merck Responds To Questions About Adverse Events Reported Following Vaccination With GARDASILÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚®

 

Merck has analyzed the adverse events reported for GARDASIL relating to the recent reports of death and paralysis, and based on the data available to Merck, believes that no safety issue related to the vaccine has been identified. These types of events are events that could also be seen in the general population, even in the absence of vaccination......"

Link to comment
Share on other sites

In reply to: dee27 on Tuesday 22/07/08 11:05am

CSL's main competitor is US pharma giant BAXTER; if one company is doing well then chances are so is the other one.

 

A few days ago BAXTER gave a conference call at which their senior management forecast significant earnings appreciation over the next three years.

 

At some conference on July 30 BAXTER will be announcing the results of its Phase II trials on the effectiveness of IVIG as a therapy to treat Alzheimer's disease; if, as is widely expected, this trial leads to a Phase III later in 2008 you can expect CSL's SP to move appreciably skywards.

 

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...